clofazimine has been researched along with Disease Models, Animal in 39 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China." | 8.12 | Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. ( Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H, 2022) |
| "Clofazimine and high-dose rifapentine have each separately been associated with treatment-shortening activity when incorporated into tuberculosis (TB) treatment regimens." | 7.91 | Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis. ( Ammerman, NC; Chaisson, RE; Chang, YS; Grosset, JH; Jain, S; Nuermberger, E; Saini, V; Tasneen, R, 2019) |
| "The antileprosy drug clofazimine was recently repurposed as part of a newly endorsed short-course regimen for multidrug-resistant tuberculosis." | 7.88 | Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis. ( Almeida, DV; Ammerman, NC; Bautista, EM; Bester, LA; Betoudji, F; Chaisson, RE; Chang, YS; Grosset, JH; Guo, H; Li, SY; Moodley, C; Ngcobo, B; Nuermberger, E; Omansen, TF; Pillay, L; Saini, V; Singh, SD; Swanson, RV; Tapley, A; Tasneen, R; Tyagi, S, 2018) |
| "Experimental and clinical studies have indicated that the antileprosy drug clofazimine may contribute treatment-shortening activity when included in tuberculosis treatment regimens." | 7.83 | Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy. ( Adamson, J; Almeida, DV; Ammerman, NC; Bester, LA; Dorasamy, A; Grosset, JH; Mgaga, Z; Moodley, C; Moodley, S; Ngcobo, B; Singh, SD; Swanson, RV, 2016) |
| "A key drug for the treatment of leprosy, clofazimine has recently been associated with highly effective and significantly shortened regimens for the treatment of multidrug-resistant tuberculosis (TB)." | 7.81 | Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. ( Adamson, J; Almeida, DV; Ammerman, NC; Converse, PJ; Grosset, JH; Li, SY; Swanson, RV; Tyagi, S, 2015) |
| "In linezolid-treated animals, dark-field microscopy and qPCR assessment showed no presence of treponemes after day 3 post-treatment start, serologic test did not convert to positive, CSF had no abnormalities, and RIT was negative." | 5.62 | Efficacy of linezolid on Treponema pallidum, the syphilis agent: A preclinical study. ( Giacani, L; Haynes, AM; Mayans, MV; Mitjà, O; Nieto, C; Pérez-Mañá, C; Quintó, L; Romeis, E; Ubals, M, 2021) |
| "Clofazimine has a long history of use and has demonstrated a good safety profile for a disease that requires chronic dosing for a period of time ranging 3-36 months." | 5.46 | A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. ( Beasley, FC; Chatterjee, AK; Huston, CD; Jumani, RS; Love, MS; McNamara, CW; Schultz, PG; Wright, TM, 2017) |
| "TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China." | 4.12 | Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. ( Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H, 2022) |
| "Clofazimine and high-dose rifapentine have each separately been associated with treatment-shortening activity when incorporated into tuberculosis (TB) treatment regimens." | 3.91 | Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis. ( Ammerman, NC; Chaisson, RE; Chang, YS; Grosset, JH; Jain, S; Nuermberger, E; Saini, V; Tasneen, R, 2019) |
| "The antileprosy drug clofazimine was recently repurposed as part of a newly endorsed short-course regimen for multidrug-resistant tuberculosis." | 3.88 | Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis. ( Almeida, DV; Ammerman, NC; Bautista, EM; Bester, LA; Betoudji, F; Chaisson, RE; Chang, YS; Grosset, JH; Guo, H; Li, SY; Moodley, C; Ngcobo, B; Nuermberger, E; Omansen, TF; Pillay, L; Saini, V; Singh, SD; Swanson, RV; Tapley, A; Tasneen, R; Tyagi, S, 2018) |
| "Experimental and clinical studies have indicated that the antileprosy drug clofazimine may contribute treatment-shortening activity when included in tuberculosis treatment regimens." | 3.83 | Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy. ( Adamson, J; Almeida, DV; Ammerman, NC; Bester, LA; Dorasamy, A; Grosset, JH; Mgaga, Z; Moodley, C; Moodley, S; Ngcobo, B; Singh, SD; Swanson, RV, 2016) |
| "A key drug for the treatment of leprosy, clofazimine has recently been associated with highly effective and significantly shortened regimens for the treatment of multidrug-resistant tuberculosis (TB)." | 3.81 | Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. ( Adamson, J; Almeida, DV; Ammerman, NC; Converse, PJ; Grosset, JH; Li, SY; Swanson, RV; Tyagi, S, 2015) |
| "Twenty-five compounds structurally related to clofazimine were tested for their ability to inhibit the growth of Mycobacterium leprae using the kinetic method of drug evaluation in the mouse foot pad model of leprosy." | 3.68 | Activity of phenazine analogs against Mycobacterium leprae infections in mice. ( O'Sullivan, JF; Shinnick, TM; Van Landingham, RM; Walker, LL, 1993) |
| "In linezolid-treated animals, dark-field microscopy and qPCR assessment showed no presence of treponemes after day 3 post-treatment start, serologic test did not convert to positive, CSF had no abnormalities, and RIT was negative." | 1.62 | Efficacy of linezolid on Treponema pallidum, the syphilis agent: A preclinical study. ( Giacani, L; Haynes, AM; Mayans, MV; Mitjà, O; Nieto, C; Pérez-Mañá, C; Quintó, L; Romeis, E; Ubals, M, 2021) |
| " Additional preclinical studies are required to identify the minimal dose and dosage of CFZ for babesiosis." | 1.56 | Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts. ( Gantuya, S; Guswanto, A; Igarashi, I; Krause, PJ; Sivakumar, T; Tayebwa, DS; Tuvshintulga, B; Vannier, E; Yokoyama, N, 2020) |
| "Prostate cancer was the most common form and had the second highest death rate of male cancer in the United States in 2015." | 1.51 | Photoacoustic imaging of clofazimine hydrochloride nanoparticle accumulation in cancerous vs normal prostates. ( Murashov, MD; Rosania, GR; Tan, JWY; Wang, X, 2019) |
| "As current treatment of tuberculosis is burdensomely long, provoking non-adherence and drug resistance, effective short-course treatments are needed." | 1.48 | Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility. ( Clemens, DL; Dillon, BJ; Ho, CM; Horwitz, MA; Lee, BY; Masleša-Galić, S; Nava, S; Silva, A, 2018) |
| "Clofazimine has a long history of use and has demonstrated a good safety profile for a disease that requires chronic dosing for a period of time ranging 3-36 months." | 1.46 | A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. ( Beasley, FC; Chatterjee, AK; Huston, CD; Jumani, RS; Love, MS; McNamara, CW; Schultz, PG; Wright, TM, 2017) |
| "Clofazimine was chosen for further studies because it could be effectively encapsulated and its activity was well maintained in liposomal form." | 1.29 | Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection. ( Mehta, RT, 1996) |
| " A dose-response experiment was performed with clarithromycin at 50, 100, 200, or 300 mg/kg of body weight administered daily by gavage to mice infected with approximately 10(7) viable MAC." | 1.28 | Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. ( Cynamon, MH; DeStefano, MS; Klemens, SP, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (12.82) | 18.7374 |
| 1990's | 6 (15.38) | 18.2507 |
| 2000's | 1 (2.56) | 29.6817 |
| 2010's | 20 (51.28) | 24.3611 |
| 2020's | 7 (17.95) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Ding, Y | 1 |
| Zhu, H | 2 |
| Fu, L | 3 |
| Zhang, W | 1 |
| Wang, B | 3 |
| Guo, S | 1 |
| Chen, X | 1 |
| Wang, N | 1 |
| Liu, H | 1 |
| Lu, Y | 3 |
| Tanner, L | 1 |
| Evans, JC | 1 |
| Seldon, R | 1 |
| Jordaan, A | 1 |
| Warner, DF | 1 |
| Haynes, RK | 1 |
| Parkinson, CJ | 1 |
| Wiesner, L | 1 |
| Batalha, IL | 1 |
| Bernut, A | 1 |
| Schiebler, M | 1 |
| Ouberai, MM | 1 |
| Passemar, C | 1 |
| Klapholz, C | 1 |
| Kinna, S | 1 |
| Michel, S | 1 |
| Sader, K | 1 |
| Castro-Hartmann, P | 1 |
| Renshaw, SA | 1 |
| Welland, ME | 1 |
| Floto, RA | 1 |
| Tuvshintulga, B | 1 |
| Vannier, E | 1 |
| Tayebwa, DS | 1 |
| Gantuya, S | 1 |
| Sivakumar, T | 1 |
| Guswanto, A | 1 |
| Krause, PJ | 1 |
| Yokoyama, N | 1 |
| Igarashi, I | 1 |
| Ng, PCI | 1 |
| Chan, JYW | 1 |
| Leung, RKK | 1 |
| Li, J | 1 |
| Ren, Z | 1 |
| Chan, AWH | 1 |
| Xu, Y | 1 |
| Lee, SS | 1 |
| Wang, R | 1 |
| Ji, X | 1 |
| Zheng, J | 1 |
| Chan, DPC | 1 |
| Yew, WW | 1 |
| Lee, SMY | 1 |
| Yu, W | 2 |
| Chiwala, G | 2 |
| Gao, Y | 1 |
| Liu, Z | 1 |
| Sapkota, S | 1 |
| Lu, Z | 2 |
| Guo, L | 1 |
| Khan, SA | 1 |
| Zhong, N | 2 |
| Zhang, T | 2 |
| Haynes, AM | 1 |
| Giacani, L | 1 |
| Mayans, MV | 1 |
| Ubals, M | 1 |
| Nieto, C | 1 |
| Pérez-Mañá, C | 1 |
| Quintó, L | 1 |
| Romeis, E | 1 |
| Mitjà, O | 1 |
| Yusuf, B | 1 |
| Wang, S | 1 |
| Tian, X | 1 |
| Hameed, HMA | 1 |
| Alam, MS | 1 |
| Cook, GM | 1 |
| Maslov, DA | 1 |
| Baijnath, S | 1 |
| Moodley, C | 3 |
| Ngcobo, B | 3 |
| Singh, SD | 3 |
| Kruger, HG | 1 |
| Arvidsson, PI | 1 |
| Naicker, T | 1 |
| Pym, A | 1 |
| Govender, T | 1 |
| Ammerman, NC | 4 |
| Swanson, RV | 3 |
| Bautista, EM | 1 |
| Almeida, DV | 4 |
| Saini, V | 2 |
| Omansen, TF | 1 |
| Guo, H | 1 |
| Chang, YS | 2 |
| Li, SY | 2 |
| Tapley, A | 1 |
| Tasneen, R | 3 |
| Tyagi, S | 3 |
| Betoudji, F | 1 |
| Pillay, L | 1 |
| Bester, LA | 2 |
| Chaisson, RE | 2 |
| Nuermberger, E | 2 |
| Grosset, JH | 4 |
| Lee, BY | 1 |
| Clemens, DL | 1 |
| Silva, A | 1 |
| Dillon, BJ | 1 |
| Masleša-Galić, S | 1 |
| Nava, S | 1 |
| Ho, CM | 1 |
| Horwitz, MA | 1 |
| Jain, S | 1 |
| Converse, PJ | 2 |
| Xu, J | 2 |
| Nuermberger, EL | 3 |
| Tan, JWY | 1 |
| Murashov, MD | 1 |
| Rosania, GR | 1 |
| Wang, X | 1 |
| Irwin, SM | 1 |
| Gruppo, V | 1 |
| Brooks, E | 1 |
| Gilliland, J | 1 |
| Scherman, M | 1 |
| Reichlen, MJ | 1 |
| Leistikow, R | 1 |
| Kramnik, I | 1 |
| Voskuil, MI | 1 |
| Lenaerts, AJ | 1 |
| Williams, K | 1 |
| Amoabeng, O | 1 |
| Minkowski, A | 1 |
| Mdluli, KE | 1 |
| Upton, AM | 2 |
| Adamson, J | 2 |
| Dorasamy, A | 1 |
| Moodley, S | 1 |
| Mgaga, Z | 1 |
| Sbaraglini, ML | 1 |
| Bellera, CL | 1 |
| Fraccaroli, L | 1 |
| Larocca, L | 1 |
| Carrillo, C | 1 |
| Talevi, A | 1 |
| Alba Soto, CD | 1 |
| Reeves, TM | 1 |
| Trimmer, PA | 1 |
| Colley, BS | 1 |
| Phillips, LL | 1 |
| Chuang, YM | 1 |
| Dutta, NK | 1 |
| Hung, CF | 1 |
| Wu, TC | 1 |
| Rubin, H | 1 |
| Karakousis, PC | 1 |
| Love, MS | 1 |
| Beasley, FC | 1 |
| Jumani, RS | 1 |
| Wright, TM | 1 |
| Chatterjee, AK | 1 |
| Huston, CD | 1 |
| Schultz, PG | 1 |
| McNamara, CW | 1 |
| O'Donnell, MR | 1 |
| Padayatchi, N | 1 |
| Metcalfe, JZ | 1 |
| Zhao, WJ | 1 |
| Zheng, MQ | 1 |
| Li, P | 2 |
| Liang, BW | 1 |
| Mdluli, K | 1 |
| Jin, H | 1 |
| Zheng, M | 1 |
| Zhao, W | 1 |
| Zhang, M | 1 |
| Sala, C | 1 |
| Hartkoorn, RC | 1 |
| Dhar, N | 1 |
| Mendoza-Losana, A | 1 |
| Cole, ST | 1 |
| Moschella, SL | 1 |
| Binford, CH | 1 |
| Meyers, WM | 1 |
| Walsh, GP | 1 |
| Van Landingham, RM | 1 |
| Walker, LL | 1 |
| O'Sullivan, JF | 1 |
| Shinnick, TM | 1 |
| Sison, JP | 1 |
| Yao, Y | 1 |
| Kemper, CA | 1 |
| Hamilton, JR | 1 |
| Brummer, E | 1 |
| Stevens, DA | 1 |
| Deresinski, SC | 1 |
| Mehta, RT | 2 |
| Kansal, RG | 1 |
| Gomez-Flores, R | 1 |
| Sinha, I | 1 |
| Peters, K | 1 |
| Leitzke, S | 1 |
| Diederichs, JE | 1 |
| Borner, K | 1 |
| Hahn, H | 1 |
| Müller, RH | 1 |
| Ehlers, S | 1 |
| Leiker, DL | 1 |
| Gangadharam, PR | 1 |
| Parikh, K | 1 |
| Klemens, SP | 1 |
| DeStefano, MS | 1 |
| Cynamon, MH | 1 |
| Evans, AT | 1 |
| Croft, SL | 1 |
| Peters, W | 1 |
| Neal, RA | 1 |
| Shepard, CC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of Clofazimine (CFZ) in Cryptosporidiosis[NCT03341767] | Phase 2 | 33 participants (Actual) | Interventional | 2017-12-14 | Terminated (stopped due to Insufficient accrual rate) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for clofazimine and Disease Models, Animal
| Article | Year |
|---|---|
Elucidating the role of clofazimine for the treatment of tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Dose-Response Relationship, Dru | 2016 |
Chemotherapy in Leprosy.
Topics: Acetamides; Anemia, Hemolytic; Aniline Compounds; Animals; Clofazimine; Dapsone; Disease Models, Ani | 1975 |
The first decade in experimental leprosy.
Topics: Animals; BCG Vaccine; Clofazimine; Dapsone; Disease Models, Animal; Drug Evaluation; Drug Evaluation | 1971 |
1 trial available for clofazimine and Disease Models, Animal
| Article | Year |
|---|---|
Treatment of Myocardium avium complex infection: does the beige mouse model predict therapeutic outcome in humans?
Topics: AIDS-Related Opportunistic Infections; Animals; Antitubercular Agents; Clofazimine; Colony Count, Mi | 1996 |
35 other studies available for clofazimine and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Isoniazid; Li | 2022 |
Topics: Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Mice; Microbial Sensitivity Tes | 2019 |
Polymeric nanobiotics as a novel treatment for mycobacterial infections.
Topics: Animals; Antitubercular Agents; Clofazimine; Delayed-Action Preparations; Disease Models, Animal; Dr | 2019 |
Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts.
Topics: Amino Acid Sequence; Animals; Babesia microti; Babesiosis; Clofazimine; Cytochromes b; Disease Model | 2020 |
Role of oxidative stress in clofazimine-induced cardiac dysfunction in a zebrafish model.
Topics: Acetylcysteine; Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Gene Expression | 2020 |
TB47 and clofazimine form a highly synergistic sterilizing block in a second-line regimen for tuberculosis in mice.
Topics: Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Drug Synergism; Female; Imidazo | 2020 |
Efficacy of linezolid on Treponema pallidum, the syphilis agent: A preclinical study.
Topics: Animals; Area Under Curve; Clofazimine; Disease Models, Animal; Drug Evaluation, Preclinical; Linezo | 2021 |
Sterilizing Effects of Novel Regimens Containing TB47, Clofazimine, and Linezolid in a Murine Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Linezolid; Mice; Mice, Inbred B | 2021 |
Clofazimine protects against Mycobacterium tuberculosis dissemination in the central nervous system following aerosol challenge in a murine model.
Topics: Animals; Antitubercular Agents; Blood-Brain Barrier; Brain; Clofazimine; Disease Models, Animal; Fem | 2018 |
Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Female; Mice; Mice, Inbred BALB | 2018 |
Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility.
Topics: Adamantane; Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; D | 2018 |
Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Clofazimine; Disease Models, Animal; Dr | 2019 |
Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Buruli Ulcer; Clarithromycin; Clofazimine; Disease M | 2019 |
Photoacoustic imaging of clofazimine hydrochloride nanoparticle accumulation in cancerous vs normal prostates.
Topics: Adenocarcinoma; Animals; Chlorides; Clofazimine; Contrast Media; Disease Models, Animal; Male; Mice; | 2019 |
Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas.
Topics: Animals; Antitubercular Agents; Bacterial Load; Clofazimine; Disease Models, Animal; Female; Granulo | 2014 |
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Therapy, | 2015 |
Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Female; Mice; Mice, Inbred BALB | 2015 |
Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.
Topics: Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Drug Combinations; Drug Therapy | 2016 |
Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease.
Topics: Adult; Animals; Antiprotozoal Agents; Chagas Disease; Chronic Disease; Clofazimine; Cysteine Endopep | 2016 |
Targeting Kv1.3 channels to reduce white matter pathology after traumatic brain injury.
Topics: Action Potentials; Animals; Animals, Newborn; Brain Injuries, Traumatic; Calcium-Binding Proteins; C | 2016 |
Stringent Response Factors PPX1 and PPK2 Play an Important Role in Mycobacterium tuberculosis Metabolism, Biofilm Formation, and Sensitivity to Isoniazid In Vivo.
Topics: Acid Anhydride Hydrolases; Animals; Antitubercular Agents; Biofilms; Citric Acid Cycle; Clofazimine; | 2016 |
A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
Topics: Animals; Antiprotozoal Agents; Automation, Laboratory; Cell Line; Clofazimine; Cryptosporidiosis; Cr | 2017 |
[A study on the activity of clofazimine with antituberculous drugs against Mycobacterium tuberculosis].
Topics: Animals; Antitubercular Agents; Clarithromycin; Clofazimine; Disease Models, Animal; Drug Synergism; | 2010 |
In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters.
Topics: Animals; Antitubercular Agents; Aza Compounds; Chronic Disease; Clofazimine; Disease Models, Animal; | 2012 |
Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis.
Topics: Acetamides; Amino Acid Sequence; Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Dise | 2012 |
Leprosy today.
Topics: Clofazimine; Dapsone; Disease Models, Animal; Drug Resistance, Microbial; Humans; Leprosy; Mycobacte | 1983 |
Leprosy.
Topics: Animals; Armadillos; Cercopithecidae; Clofazimine; Cricetinae; Disease Models, Animal; Female; Human | 1982 |
Activity of phenazine analogs against Mycobacterium leprae infections in mice.
Topics: Abdomen; Adipose Tissue; Animals; Clofazimine; Disease Models, Animal; Drug Evaluation, Preclinical; | 1993 |
Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.
Topics: Animals; Anti-Bacterial Agents; Cells, Cultured; Clofazimine; Disease Models, Animal; Drug Carriers; | 1996 |
Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Chronic Disease; Clofazimine; Disease Models, Animal; | 1997 |
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection.
Topics: Animals; Anti-Bacterial Agents; Clofazimine; Disease Models, Animal; Drug Carriers; Female; Freeze D | 2000 |
In-vivo activity of streptomycin and clofazimine against established infections of Mycobacterium avium complex in beige mice.
Topics: Animals; Clofazimine; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Ma | 1992 |
Activity of clarithromycin against Mycobacterium avium complex infection in beige mice.
Topics: Amikacin; Animals; Anti-Infective Agents; Antitubercular Agents; Clarithromycin; Clofazimine; Diseas | 1992 |
Antileishmanial effects of clofazimine and other antimycobacterial agents.
Topics: Administration, Topical; Animals; Antitubercular Agents; Cells, Cultured; Clofazimine; Disease Model | 1989 |